Ameloblastic sarcoma: pathogenesis and treatment with chemotherapy.
A recurrent tumor in a young male demonstrates the progression of an ameloblastic fibroma to an ameloblastic sarcoma. Chemotherapy with Actinomycin D, Vincristine, and Cytoxan produced a complete response without evidence of recurrence 4 years after initiation of chemotherapy. The patient developed an aggressive malignant melanoma 1 year after all chemotherapy was discontinued.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006258:Head and Neck Neoplasms / Q000150:complications; D006801:Humans; D007573:Jaw Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D008297:Male; D008545:Melanoma / Q000150:complications; D009364:Neoplasm Recurrence, Local; D009378:Neoplasms, Multiple Primary; D009808:Odontogenic Tumors / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide